This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NeoStem To Present At Multiple September Conferences

Stocks in this article: NBS

NEW YORK, Sept. 3, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, announced today that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple upcoming conferences in September.

European Society of Cardiology Congress: Acute Cardiac Care 2013

  • Date and Time: Tuesday, September 3, 3:30 PM CEST
  • Venue: Congress Centre, Amsterdam, The Netherlands
  • Session: Infarction acute phase STEMI (Moderated posters)
  • Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development and Regulatory Affairs

Rodman & Renshaw 15 th Annual Healthcare Conference

  • Date and Time: Monday, September 9, 10:50 AM EDT
  • Venue: Millennium Broadway Hotel, New York, New York
  • Session: Company presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

International Society for Cellular Therapy (ISCT) North American Regional Meeting 2013

  • Date and Time: Tuesday, September 10, 10:30 AM EDT
  • Venue: Hyatt at Penn's Landing, Philadelphia, Pennsylvania
  • Session: Commercialization Case Study: Cell Therapy from Concept to Market
  • Speaker: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, Progenitor Cell Therapy (PCT)

Stifel Annual Healthcare Conference 2013

  • Date and Time: Wednesday, September 11, 2:40 PM EDT
  • Venue: Four Seasons Hotel, Boston, Massachusetts
  • Session: Company presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

Heart Failure Society of America 17th Annual Scientific Meeting

  • Date and Time: Monday, September 23, 4:00 PM EDT
  • Venue: The Peabody Orlando Hotel, Orlando, Florida
  • Session: Can Cell Therapy Put Systolic Heart Failure on the Endangered Species List?
  • Speaker: Douglas W. Losordo, MD, FACC, FAHA, Chief Medical Officer

Aegis Capital Corp. 2013 Healthcare Conference

  • Date and Time: Thursday, September 26, 9:00 AM PDT
  • Venue: The Encore at Wynn, Las Vegas, Nevada
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

BioCentury Newsmakers in the Biotech Industry

  • Date and Time: Friday, September 27, 10:00 AM EDT
  • Venue: The Millennium Broadway Hotel & Conference Center, New York, New York
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

The Symposium on Advanced Wound Care

  • Date and Time: Saturday, September 28, 4:10 PM PDT
  • Venue: Bally's Las Vegas, Las Vegas, Nevada
  • Session: Cell Therapy for Critical Limb Ischemia
  • Speaker: Douglas W. Losordo, MD, FACC, FAHA, Chief Medical Officer

Stem Cells & Regenerative Medicine Congress

  • Date and Time: Monday, September 30, 1:50 PM EDT
  • Venue: The Hyatt Regency, Cambridge, Massachusetts
  • Session: Capital formation strategies for stem cell and regenerative medicine companies
  • Session Chair: Robin L. Smith, MD, MBA, Chairman and CEO

About NeoStem

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs